Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China.
Front Genet
; 13: 1000448, 2022.
Article
in En
| MEDLINE
| ID: mdl-36160021
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Front Genet
Year:
2022
Document type:
Article
Affiliation country:
China